Business Context and Reporting Period
Company: Becton, Dickinson and Company (BD)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended September 30, 2004
Industry: Medical Technology (Medical supplies, devices, laboratory equipment, and diagnostic products)
BD operates through three worldwide business segments: BD Medical, BD Diagnostics, and BD Biosciences. The company manufactures and sells products to healthcare institutions, life science researchers, clinical laboratories, and the general public. As of September 30, 2004, BD employed 25,005 people globally.
Key Financial Metrics
Note: Specific consolidated revenue, net income, cash flow, and debt figures are incorporated by reference to Exhibit 13 (Annual Report to Shareholders) and are not explicitly detailed in the provided text. The following metrics are available from the filing text:
- Research and Development (R&D) Spend: $236 million for fiscal 2004 (compared to $224 million in 2003 and $207 million in 2002).
- Valuation and Qualifying Accounts (Trade Receivables):
- Balance at end of 2004: $52.4 million (Total allowance for doubtful accounts and cash discounts).
- Additions charged to costs/expenses in 2004: $27.8 million.
- Stock Repurchases (Q3 2004): Purchased 2,109,528 shares at an average price of $47.50 per share.
- Settlement Costs: Paid $100 million to settle an antitrust lawsuit with Retractable Technologies, Inc. (RTI) in July 2004.
Material Changes and Operational Updates
- Acquisition: In July 2004, BD acquired Atto Bioscience, Inc., a company specializing in optical instrumentation for real-time analysis of living cells. Results are included in the BD Biosciences segment.
- Divestiture: In September 2004, the Board approved a plan to sell the Clontech unit of the BD Biosciences segment. Clontech results are reported as Discontinued Operations.
- Legal Settlement: Settled a lawsuit with Retractable Technologies, Inc. for $100 million, dismissing claims of antitrust violations and business disparagement.
- Customer Concentration: Sales to a single U.S. distributor accounted for approximately 11% of total revenues in fiscal 2004.
Outlook, Risks, and Contingencies
Management Commentary and Risks:
- Forward-Looking Statements: BD cautions that actual results may differ due to economic factors, currency fluctuations, competitive pricing pressures, and changes in healthcare reimbursement policies.
- Regulatory Environment: Operations are subject to strict regulation by the FDA and foreign agencies. Regulatory changes can impact product development timelines and costs.
- Legal Proceedings:
- Latex Gloves Litigation: BD is a defendant in approximately 523 product liability lawsuits regarding natural rubber latex allergies. Most cases have been closed with no liability; remaining cases are being vigorously defended.
- Needlestick Litigation: Four pending class action lawsuits allege accidental needlesticks. BD opposes class certification.
- False Claims Act: A qui tam complaint has been filed alleging violations of the Federal False Claims Act; the matter is under seal.
- Patent Disputes: BD is involved in patent infringement suits with Greiner (UK) and Therasense (US).
- Environmental Matters: BD is a party to Superfund proceedings. While current accruals are deemed sufficient, future charges could be material.
Investor Verification Checklist
- Verify the final sale price and terms of the Clontech divestiture, as the transaction was approved but not yet completed at the time of filing.
- Review the full "Ten-Year Summary of Selected Financial Data" in Exhibit 13 for consolidated revenue, net income, and cash flow figures not present in this summary.
- Monitor the status of the pending qui tam complaint under the Federal False Claims Act and the outcome of the latex glove and needlestick class action certifications.
- Assess the impact of the $100 million RTI settlement on future profitability and legal reserves.
- Confirm the integration progress of the Atto Bioscience acquisition into the BD Biosciences segment.